1. Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn’s Disease
- Author
-
Nathalie Khoury, Fares Yared, Rita Jabbour, Ziad Bakouny, Joseph Bou Jaoude, Elie El Rassy, Rachel Hallit, and Khalil Honein
- Subjects
medicine.medical_specialty ,Placebo ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Recurrence ,Internal medicine ,Secondary Prevention ,Adalimumab ,medicine ,Humans ,Postoperative Period ,Prospective cohort study ,Crohn's disease ,Tumor Necrosis Factor-alpha ,business.industry ,Gastroenterology ,Odds ratio ,medicine.disease ,Infliximab ,Confidence interval ,030220 oncology & carcinogenesis ,Meta-analysis ,Tumor Necrosis Factor Inhibitors ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Introduction There is a lack of studies on the optimal anti-tumor necrosis factor (anti-TNF) agent for postoperative prophylaxis of Crohn's disease (CD) recurrence. Therefore, we conducted a network meta-analysis (NMA) of prospective trials to compare the efficacy of anti-TNF agents in the prevention of postoperative endoscopic and clinical recurrence of CD following ileocolonic resection. Methods We searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, and recent American gastroenterology association (AGA) meeting abstracts through August 2017. We selected prospective studies comparing anti-TNF agents among each other or to other agents in the setting of postoperative prevention of CD recurrence. We performed a NMA using a frequentist approach with generalized pairwise modeling and inverse variance heterogeneity method. Results We identified 9 studies, including 571 patients and 5 treatment agents, among which 2 anti-TNF drugs (adalimumab and infliximab). Compared with infliximab, our NMA yielded the following results for endoscopic recurrence: adalimumab [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.18-4.75], thiopurines (OR, 4.11; 95% CI, 0.68-24.78), placebo (OR, 4.39; 95% CI, 0.70-27.68), and Mesalamine (OR, 37.84; 95% CI, 3.77-379.42). For clinical recurrence: adalimumab (OR, 1.03; 95% CI, 0.17-6.03), thiopurines (OR, 1.40; 95% CI, 0.20-10.02), placebo (OR, 1.77; 95% CI, 1.01-3.10), and mesalamine (OR, 16.54; 95% CI, 1.55-176.24). Conclusions On the basis of a NMA combining direct and indirect evidence either adalimumab or infliximab may be used in the postoperative prophylaxis of CD recurrence. There is currently a lack of evidence on the use of other anti-TNF agents in this setting.
- Published
- 2019
- Full Text
- View/download PDF